← All Xbiotech INC filings

Xbiotech INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
XBIT
Xbiotech INC
SCHEDULE: W. Thorpe McKenzie Boosts XBIOTECH Stake to 9.76%
W. Thorpe McKenzie has reported beneficial ownership of 9.76% of XBIOTECH INC.'s common shares as of December 31, 2025.
NASDAQ
XBIT
Xbiotech INC
SCHEDULE: XBiotech Chairman Boosts Stake to 17.7%
XBiotech Inc.'s Chairman of the Board, John Simard, reported beneficial ownership of 17.7% of the company's common shares as of December 31, 2025.
NASDAQ
XBIT
Xbiotech INC
SCHEDULE 13G/A: W. Thorpe McKenzie Discloses 9.71% Passive Stake in XBIOTECH, INC.
W. Thorpe McKenzie has filed an amended Schedule 13G, reporting a 9.71% beneficial ownership stake in XBIOTECH, INC. as of December 31, 2024.
NASDAQ
XBIT
Xbiotech INC
SCHEDULE 13G/A: XBiotech CEO John Simard Increases Beneficial Ownership to 19.9% Through Convertible Loan and Options
XBiotech Inc. CEO John Simard has increased his beneficial ownership in the company to 19.9% of common shares, primarily through a convertible loan and exercisable stock options.